Literature DB >> 31352481

The Consensus Hepatitis C Cascade of Care: Standardized Reporting to Monitor Progress Toward Elimination.

Kelly Safreed-Harmon1, Sarah Blach2, Soo Aleman3,4, Signe Bollerup5, Graham Cooke6, Olav Dalgard7,8, John F Dillon9, Gregory J Dore10, Ann-Sofi Duberg11, Jason Grebely10, Knut Boe Kielland12, Håvard Midgard13, Kholoud Porter14, Homie Razavi2, Mark Tyndall15, Nina Weis5,16, Jeffrey V Lazarus1,17.   

Abstract

Cascade-of-care (CoC) monitoring is an important component of the response to the global hepatitis C virus (HCV) epidemic. CoC metrics can be used to communicate, in simple terms, the extent to which national and subnational governments are advancing on key targets, and CoC findings can inform strategic decision-making regarding how to maximize the progression of individuals with HCV to diagnosis, treatment, and cure. The value of reporting would be enhanced if a standardized approach were used for generating CoCs. We have described the Consensus HCV CoC that we developed to address this need and have presented findings from Denmark, Norway, and Sweden, where it was piloted. We encourage the uptake of the Consensus HCV CoC as a global instrument for facilitating clear and consistent reporting via the World Health Organization (WHO) viral hepatitis monitoring platform and for ensuring accurate monitoring of progress toward WHO's 2030 hepatitis C elimination targets.
© The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  cascade of care; disease elimination; hepatitis C virus; monitoring; policy

Mesh:

Year:  2019        PMID: 31352481     DOI: 10.1093/cid/ciz714

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  13 in total

1.  Association of Referral Source and Substance Use with Hepatitis C Virus Outcomes at a Southern Academic Medical Center.

Authors:  H Jensie Burton; Aastha Khatiwada; Dongjun Chung; Eric G Meissner
Journal:  South Med J       Date:  2022-06       Impact factor: 0.810

2.  Care Facilitation Advances Movement Along the Hepatitis C Care Continuum for Persons With Human Immunodeficiency Virus, Hepatitis C, and Substance Use: A Randomized Clinical Trial (CTN-0064).

Authors:  Lisa R Metsch; Daniel J Feaster; Lauren K Gooden; Carmen Masson; David C Perlman; Mamta K Jain; Tim Matheson; C Mindy Nelson; Petra Jacobs; Susan Tross; Louise Haynes; Gregory M Lucas; Jonathan A Colasanti; Allan Rodriguez; Mari-Lynn Drainoni; Georgina Osorio; Ank E Nijhawan; Jeffrey M Jacobson; Meg Sullivan; David Metzger; Pamela Vergara-Rodriguez; Ronald Lubelchek; Rui Duan; Jacob N Batycki; Abigail G Matthews; Felipe Munoz; Eve Jelstrom; Raul Mandler; Carlos Del Rio
Journal:  Open Forum Infect Dis       Date:  2021-06-27       Impact factor: 4.423

3.  Psychosocial Factors and the Care Cascade for Hepatitis C Treatment Colocated at a Syringe Service Program.

Authors:  Daniel Winetsky; Daniel Burack; Pantelis Antoniou; Bill Garcia; Peter Gordon; Matthew Scherer
Journal:  J Infect Dis       Date:  2020-09-02       Impact factor: 5.226

4.  Opportunistic co-screening for HCV and COVID-19-related services: A creative response with a need for thoughtful reflection.

Authors:  Loreta A Kondili; Lucia Craxì; Massimo Andreoni; Francesco S Mennini; Homie Razavi
Journal:  Liver Int       Date:  2022-05       Impact factor: 8.754

5.  The impact of universal access to direct-acting antiviral therapy on the hepatitis C cascade of care among individuals attending primary and community health services.

Authors:  Michael W Traeger; Alisa E Pedrana; Daniela K van Santen; Joseph S Doyle; Jessica Howell; Alexander J Thompson; Carol El-Hayek; Jason Asselin; Victoria Polkinghorne; Dean Membrey; Fran Bramwell; Allison Carter; Rebecca Guy; Mark A Stoové; Margaret E Hellard
Journal:  PLoS One       Date:  2020-06-30       Impact factor: 3.240

6.  Hepatitis C treatment uptake among people who inject drugs in the oral direct-acting antiviral era.

Authors:  Oluwaseun Falade-Nwulia; Rachel E Gicquelais; Jacquie Astemborski; Sean D McCormick; Greg Kirk; Mark Sulkowski; David L Thomas; Shruti H Mehta
Journal:  Liver Int       Date:  2020-10       Impact factor: 8.754

Review 7.  Accelerating the elimination of hepatitis C in Kuwait: An expert opinion.

Authors:  Fuad Hasan; Ahmad Alfadhli; Abeer Al-Gharabally; Mahmoud Alkhaldi; Massimo Colombo; Jeffrey V Lazarus
Journal:  World J Gastroenterol       Date:  2020-08-14       Impact factor: 5.742

8.  A micro-elimination approach to addressing hepatitis C in Turkey.

Authors:  Ramazan Idilman; Homie Razavi; Sarah Robbins-Scott; Ulus Salih Akarca; Necati Örmeci; Sabahattin Kaymakoglu; Bilgehan Aygen; Nurdan Tozun; Rahmet Güner; Hurrem Bodur; Jeffrey V Lazarus
Journal:  BMC Health Serv Res       Date:  2020-03-24       Impact factor: 2.655

Review 9.  Loss to follow-up in the hepatitis C care cascade: A substantial problem but opportunity for micro-elimination.

Authors:  Marleen van Dijk; Joost P H Drenth
Journal:  J Viral Hepat       Date:  2020-09-22       Impact factor: 3.728

10.  Hepatitis C Virus Prevalence and Risk Factors in a Village in Northeastern Romania-A Population-Based Screening-The First Step to Viral Micro-Elimination.

Authors:  Laura Huiban; Carol Stanciu; Cristina Maria Muzica; Tudor Cuciureanu; Stefan Chiriac; Sebastian Zenovia; Vladut Mirel Burduloi; Oana Petrea; Ana Maria Sîngeap; Irina Gîrleanu; Cătălin Sfarti; Camelia Cojocariu; Anca Trifan
Journal:  Healthcare (Basel)       Date:  2021-05-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.